[Preprint] Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing anchored RBD: a randomised, observer-blind, phase 1 study

Wataru Akahata of VLP Therapeutics Japan and colleagues posted on November 22 a preprint* “Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing anchored RBD: a randomised, observer-blind, phase 1 study” on medRxiv, a preprint server for health sciences.

*Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information (source).

• See the preprint abstract (full text also available): https://www.medrxiv.org/content/10.1101/2022.11.21.22281000v1